# Acute Interstitial Nephritis: Complete Etiology and Etiology-Directed Treatment

## How to Read This Page — Evidence Provenance

AIN has essentially no randomized treatment evidence — with exactly one exception, noted in the IgG4 section. Rather than blur that, every substantive claim on this page carries a provenance tag. EVIDENCE-BASED

Anchored to a named, citable source with a PMID, listed in [Sources](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources). The claim came from the literature, not from habit.

PRACTICE-BASED

Clinical experience and conventional nephrology teaching where the literature is thin or absent. Real and useful — but you should know which is which before you act on it.

Why this matters more here than in most topics

The entire second-line drug literature in AIN rests on case series in the **single digits**. When a treatment recommendation below is tagged PRACTICE-BASED, that is not hedging — it is an accurate description of the state of the field.

------------------------------------------------------------------------

## 1. Definition and Mechanism

EVIDENCE-BASED Acute interstitial nephritis is immune-mediated inflammation of the renal interstitium and tubules with the glomeruli spared, accounting for **5–15% of AKI** among hospitalized patients and roughly 15–27% of biopsies performed for unexplained AKI^([1,3,4](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

EVIDENCE-BASED The effector mechanism is **T-cell mediated delayed-type hypersensitivity**^([1,2](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). Drug or metabolite haptenizes native tubular protein, generating a neo-antigen; CD4+ helper T cells recognize the drug-laden tubular epithelium; a mixed infiltrate of T cells and eosinophils enters the interstitium; cytotoxic T cells attack tubular epithelium. Interstitial edema and infiltrate dominate, with **minimal tubular necrosis** — the key histologic separation from ATN.

The single fact that drives the whole treatment section

Because the effector is a **T cell**, B-cell–directed therapy is mechanistically mismatched in ordinary drug-induced AIN. This is why rituximab — the most common second-line question — does not belong here, and why it *does* belong in the antibody-mediated variants. Hold this thought through Section 6.

EVIDENCE-BASED The reaction is **not dose-dependent** and **recurs rapidly on re-exposure** — both hallmarks of an allergic rather than toxic mechanism^([2,3](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

------------------------------------------------------------------------

## 2. Etiology I — Drugs

EVIDENCE-BASED Drug exposure accounts for roughly **70–75%** of biopsy-proven AIN. Within that, pooled biopsy series place **antibiotics at approximately 49%, PPIs at approximately 14%, and NSAIDs at approximately 11%**, with omeprazole the most implicated single agent (approximately 12%) and amoxicillin second (approximately 8%)^([1,4](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

Latency is agent-specific — the “2 to 8 weeks” rule is a trap

Antibiotics **1–3 weeks** · PPIs **3–6 months** · checkpoint inhibitors **3–12 months** · mesalamine **months to years**. The most commonly missed AIN in practice is a slow creatinine drift on a chronic PPI, written off as CKD progression.

### 2.1 Antibiotics EVIDENCE-BASED

| Class | Agents | Distinguishing features |
|----|----|----|
| **Penicillins** | Methicillin (historical), nafcillin, oxacillin, amoxicillin, ampicillin, piperacillin | Hapten mechanism. Methicillin/nafcillin historically produced the full triad at high frequency; modern agents rarely do^([2](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) |
| **Cephalosporins** | All generations | **Cross-reactive with penicillins** — avoid both classes after either |
| **Sulfonamides** | TMP-SMX, sulfadiazine | Frequent culprit; also a DRESS trigger. Governs the PJP prophylaxis choice in Section 7 |
| **Fluoroquinolones** | Ciprofloxacin (most reported), levofloxacin, moxifloxacin | Can follow a single dose; granulomatous variants described^([1,20](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) |
| **Glycopeptides** | Vancomycin | **Overlapping AIN and ATN** on the same biopsy; also a DRESS trigger |
| **Rifamycins** | Rifampin | **Distinct mechanism — anti-rifampin antibodies**, not classic haptenization. Flu-like syndrome, hemolysis, thrombocytopenia; often dialysis-requiring; typically after intermittent dosing or re-exposure^([19](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) |
| **Others** | Macrolides, tetracyclines (minocycline), linezolid, daptomycin | Minocycline also causes drug-induced lupus and DRESS |

### 2.2 Gastrointestinal agents EVIDENCE-BASED

**Proton pump inhibitors** — a class effect across omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, and dexlansoprazole. Cross-reactivity is near-universal, so **switching to a different PPI after PPI-AIN is not a solution**; famotidine is the substitute when acid suppression is genuinely required. The presentation is insidious — sterile pyuria or a bland sediment with a creatinine that drifts rather than jumps. Population data link PPI exposure to incident CKD, and AIN is a principal proposed mechanism^([1,10](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

**5-aminosalicylates** — mesalamine, sulfasalazine, balsalazide, olsalazine. A systematic review of 5-ASA–induced interstitial nephritis in IBD and a dedicated review of mesalamine and kidney disease both describe an **insidious course over months to years that is frequently irreversible** when recognized late, supporting baseline and periodic creatinine monitoring^([11,12](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

### 2.3 NSAIDs EVIDENCE-BASED

All non-selective agents and COX-2 selective agents. Two features set this subtype apart^([1,13](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)):

- **It does not respond to glucocorticoids** — the single most important treatment exception on this page.
- It may present with **concurrent nephrotic-range proteinuria** from minimal-change overlap, which is unusual for AIN generally.

PRACTICE-BASED Topical NSAIDs are systemically absorbed and are routinely discounted by patients and clinicians alike. Ask about gels and patches by name.

### 2.4 Immune checkpoint inhibitors EVIDENCE-BASED

PD-1 agents (pembrolizumab, nivolumab, cemiplimab), PD-L1 agents (atezolizumab, durvalumab, avelumab), and CTLA-4 agents (ipilimumab, tremelimumab). Multicenter clinicopathologic series established AIN as the dominant renal lesion, characterized the extended latency, and defined outcomes and rechallenge experience^([14,15,16](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

The checkpoint-inhibitor attribution trap

Most patients on a checkpoint inhibitor are **also on a PPI**, and concurrent PPI exposure is a recognized confounder in attributing the lesion^([14,15](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). Before you stop a cancer drug the patient needs, account for the PPI they do not. Stopping the PPI is free. Stopping immunotherapy is not.

### 2.5 Allopurinol and urate-lowering therapy EVIDENCE-BASED

Allopurinol is among the most severe drug causes, typically presenting as full DRESS — fever, rash, eosinophilia, hepatitis, and AKI. Risk is concentrated in **HLA-B\*58:01 carriers** (Han Chinese, Thai, Korean ancestry) and is **further amplified by renal impairment**, a combination directly examined in the dermatologic literature^([17](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). PRACTICE-BASED Concurrent thiazide use is conventionally cited as an additional risk multiplier; febuxostat is the usual alternative, though cross-reactivity is described.

### 2.6 Anticonvulsants and other agents PRACTICE-BASED

The aromatic anticonvulsants — phenytoin, carbamazepine, phenobarbital — cross-react with one another and usually present as anticonvulsant hypersensitivity syndrome rather than isolated AIN. Switch to a non-aromatic agent (levetiracetam, valproate, gabapentin). Also reported: thiazide and loop diuretics (both sulfonamide-based), hydralazine (which also causes drug-induced lupus and ANCA vasculitis — check ANCA and anti-histone), statins, and rarely ACE inhibitors and ARBs.

### 2.7 DRESS — the drugs that cause it EVIDENCE-BASED

Renal involvement in DRESS *is* AIN. The RegiSCAR prospective study characterized the syndrome, its validated scoring, its 2–8 week latency — longer than ordinary drug hypersensitivity — and its tendency to relapse during steroid taper^([18](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). High-risk agents cluster tightly:

**Allopurinol · aromatic anticonvulsants · sulfonamides · vancomycin · minocycline · dapsone · abacavir · nevirapine**

### 2.8 Aristolochic acid — not AIN, and it matters EVIDENCE-BASED

Aristolochic acid produces a relentlessly progressive fibrosing interstitial nephropathy with a high rate of upper-tract urothelial carcinoma. It is **not steroid-responsive**, and recognizing it changes surveillance rather than immunosuppression^([21](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). Ask about herbal and traditional preparations explicitly.

------------------------------------------------------------------------

## 3. Etiology II — Infection, Autoimmune, Malignancy, Genetic

### 3.1 Infection PRACTICE-BASED

Roughly 5–10% of AIN. The therapeutic implication is **inverted** from drug-induced disease: treat the organism, and steroids are generally contraindicated.

- **Bacterial:** *Streptococcus*, *Staphylococcus*, *Legionella*, *Brucella*, *Salmonella*, *Campylobacter*, *Yersinia*, *Mycoplasma*, *Leptospira*, *M. tuberculosis*, syphilis, *Coxiella burnetii*
- **Viral:** EBV, CMV, HIV, hantavirus, **BK polyomavirus** (allograft), adenovirus, parvovirus B19, hepatitis B and C, SARS-CoV-2, dengue
- **Fungal / parasitic:** *Histoplasma*, *Coccidioides*, *Leishmania*, *Toxoplasma*, *Schistosoma*

EVIDENCE-BASED BK polyomavirus nephropathy is the exception that proves the rule: management is **reduction of immunosuppression**, not addition, and is governed by international consensus guidelines^([22](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

### 3.2 Systemic and autoimmune disease

| Disease | Renal signature | Anchor |
|----|----|----|
| **Sarcoidosis** | Granulomatous interstitial nephritis; hypercalcemia and hypercalciuria | EVIDENCE-BASED^([20,23](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) |
| **Sjögren disease** | Interstitial nephritis with **distal (type 1) RTA**, hypokalemia, nephrocalcinosis | EVIDENCE-BASED^([24](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) |
| **IgG4-related disease** | IgG4-rich plasma cell infiltrate, storiform fibrosis, mass-like lesions | EVIDENCE-BASED^([27,28](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) |
| **TINU syndrome** | Interstitial nephritis with bilateral anterior uveitis; young women; elevated urinary beta-2 microglobulin | EVIDENCE-BASED^([25](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) |
| **Anti-brush border antibody (ABBA) disease** | Antibodies to LRP2/megalin on the proximal tubular brush border; elderly, often progressive | EVIDENCE-BASED^([26](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) |
| **SLE** | Lupus interstitial nephritis; can occur isolated, without glomerular disease | PRACTICE-BASED |
| **Anti-TBM antibody disease** | **Linear TBM staining on immunofluorescence** | PRACTICE-BASED |
| **Inflammatory bowel disease** | Interstitial nephritis as an extraintestinal manifestation | EVIDENCE-BASED^([11,12](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) |

The IBD fork — two causes, opposite treatments

A Crohn or ulcerative colitis patient on mesalamine with interstitial nephritis has two candidate causes pointing in **opposite therapeutic directions**: mesalamine toxicity, where you stop the drug — or an extraintestinal manifestation of active IBD, where you intensify treatment^([11,12](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). Disease activity, timing relative to drug initiation, and biopsy separate them. Guessing wrong worsens the patient either way.

### 3.3 Malignancy and genetic disease

PRACTICE-BASED **Lymphoma and leukemia** infiltrate the interstitium and mimic inflammatory AIN; monoclonality on flow or immunohistochemistry makes the distinction, and the treatment is directed at the malignancy. **Myeloma and monoclonal gammopathy** require free light chains — and remember that a suppressed uninvolved chain is the clonal signal.

EVIDENCE-BASED **Karyomegalic interstitial nephritis** arises from biallelic *FAN1* mutations and shows strikingly enlarged, hyperchromatic tubular nuclei; it presents in early adulthood with progressive CKD and **has no role for immunosuppression**^([29](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). PRACTICE-BASED Autosomal dominant tubulointerstitial kidney disease (*UMOD*, *MUC1*, *REN*, *HNF1B*) belongs in the differential of unexplained interstitial disease with a bland sediment and a family history.

------------------------------------------------------------------------

## 4. Diagnosis

EVIDENCE-BASED The classic triad of fever, rash, and eosinophilia appears in **under 10%** of drug-induced AIN and is absent in over two-thirds of PPI-associated cases^([1,4](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). Its absence excludes nothing.

### 4.1 What helps — the sediment EVIDENCE-BASED

- **Sterile pyuria with WBC casts** — the most useful bedside finding^([1,3](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources))
- **Sub-nephrotic proteinuria**, usually under 1 g/day; nephrotic range points toward NSAID-associated minimal change^([13](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources))
- Cast logic: **RBC casts = GN · WBC casts = AIN · muddy brown casts = ATN**

### 4.2 What does not help — urine eosinophils EVIDENCE-BASED

Do not order urine eosinophils

Muriithi et al. compared **566 patients** who had both a urine eosinophil test and a native kidney biopsy within a week of each other; 91 had AIN. At a 1% Hansel-stain cutoff: **sensitivity 30.8%, specificity 68.2%, PPV 15.6%, NPV 83.7%**^([5](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

**The likelihood ratios settle it: LR+ 0.97 and LR− 1.01.** Both sit at 1.0, so the result moves post-test probability essentially nowhere in either direction. A test that cannot revise your estimate is not a diagnostic test. Raising the cutoff to 5% drops sensitivity to 19.8% while specificity rises to 91.2% — still not clinically useful. The test was also no better at separating AIN from ATN than from any other kidney disease.

**Why older sources disagree:** the four largest earlier series reported sensitivity 40–91% and specificity 52–95%, but **none used kidney biopsy as the gold standard**^([5](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). Those figures are an artifact of unvalidated reference standards, and they persisted in teaching material long after the biopsy-anchored data existed.

### 4.3 Biomarkers EVIDENCE-BASED

**Urinary CXCL9** is the leading non-invasive discriminator, identified and validated for AIN diagnosis by Moledina et al.^([9](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). It is mechanistically coherent — tubular epithelium secretes CXCL9 in response to IFN-gamma from the infiltrating T cells that define the lesion — and it is stable at room temperature, unlike beta-2 microglobulin, which degrades at acidic pH and saturates in heavy proteinuria. The biomarker field was reviewed in 2026^([31](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). PRACTICE-BASED Availability outside research and reference laboratories remains limited, so this rarely changes the biopsy decision today.

### 4.4 Biopsy — and what to demand from the report

PRACTICE-BASED Three items drive management more than the creatinine does:

1.  **Degree of interstitial fibrosis and tubular atrophy (IFTA)**
2.  **Presence or absence of an active inflammatory infiltrate**
3.  **Granulomas** — raising sarcoidosis, tuberculosis, fungal infection, PPIs, and fluoroquinolones^([20](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources))

------------------------------------------------------------------------

## 5. Treatment — Sorted by Etiology

### 5.1 Universal first steps EVIDENCE-BASED

- **Withdraw the offending agent** — sequentially if AKI is mild, simultaneously if severe^([1,3](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources))
- **Avoid the class and cross-reactive classes**
- **Hunt the over-the-counter exposures** — PPIs and NSAIDs go unreported because patients do not classify them as medications

Do not delay withdrawal awaiting biopsy

Withdrawal is reversible. The fibrosis from a two-week delay is not.

### 5.2 The etiology-directed table

PRACTICE-BASED except where a row carries a citation. The IgG4 row is the only one supported by randomized data.

| Etiology | First line | Then | Do NOT |
|----|----|----|----|
| **Drug-induced (general)** | Withdraw; prednisone 1 mg/kg/day if severe or not recovering^([6](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | Extend steroids to 8–12 weeks if active infiltrate → MMF 1–2 g/day^([7](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | Escalate when IFTA is heavy and infiltrate absent |
| **NSAID-induced** | Withdrawal and supportive care only^([13](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | — | **Give steroids — this subtype does not respond** |
| **PPI-induced** | Withdraw; famotidine if acid suppression needed^([10](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | Steroids if not recovering → MMF | **Switch to another PPI** |
| **Mesalamine / 5-ASA** | Withdraw permanently; steroids if inflammation active^([11,12](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | — | Rechallenge; confuse with IBD-associated nephritis |
| **Allopurinol / DRESS** | Withdraw; prednisone 1 mg/kg/day, **longer course**, slow taper^([17,18](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | MMF or cyclosporine if steroid-dependent | Rechallenge; use a 2-week taper — DRESS relapses |
| **Checkpoint inhibitor** | Hold the ICI; prednisone 0.5–1 mg/kg/day^([14,15,16](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | MMF → infliximab or cyclophosphamide (case-level) | Stop the ICI before excluding a concurrent PPI |
| **Infection-associated** | **Treat the organism** | Supportive care | **Give steroids — generally contraindicated** |
| **BK nephropathy (allograft)** | **Reduce immunosuppression**^([22](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | IVIG, leflunomide, cidofovir — all weak evidence | Add steroids for “rejection” without excluding BK |
| **Sarcoidosis** | Prednisone 0.5–1 mg/kg/day, slow taper over 6–12 months^([23](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | Methotrexate, azathioprine, or MMF → infliximab | Reach for rituximab; overlook the hypercalcemia |
| **Sjögren** | Prednisone^([24](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | MMF or azathioprine; hydroxychloroquine adjunct | **Neglect the distal RTA** — bicarbonate and potassium repletion are treatment |
| **IgG4-related disease** | Prednisone — but **most flare on taper**^([27](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | **Rituximab or inebilizumab; obexelimab**^([28,30](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | Expect steroids alone to hold remission; delay until fibrotic |
| **TINU** | Systemic steroids **plus topical steroids for the uveitis**^([25](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | MMF or azathioprine for relapsing uveitis | Manage without ophthalmology — the courses run independently |
| **Anti-TBM / ABBA disease** | Prednisone | **Rituximab** — mechanistically rational, antibody-mediated^([26](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | — |
| **Lymphoma / myeloma** | **Treat the malignancy** | — | Immunosuppress for “AIN” |
| **Karyomegalic / genetic** | Supportive; CKD management^([29](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | Transplant | **Immunosuppress — no role** |
| **Aristolochic acid** | Cease exposure; **urothelial cancer surveillance**^([21](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | — | Expect steroids to work |

### 5.3 Glucocorticoids — the evidence genuinely conflicts EVIDENCE-BASED

| Study | Design | Finding |
|----|----|----|
| González 2008^([6](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | Retrospective multicenter, n=61 (52 treated, **9 untreated**) | Dialysis 4% vs 44%; creatinine 2.1 vs 3.7 mg/dL at 18 months; steroids within 7 days OR 6.6 (95% CI 1.3–33.6) |
| Muriithi 2014^([4](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | Retrospective, n=95 (83 prednisone, 12 not) | **No difference** in recovery at 6 months |
| Fernández-Juárez 2018^([8](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) | Retrospective, treatment-duration analysis | Examined corticosteroid duration against recovery |

Critical appraisal — do not over-read González

The nominal arithmetic gives ARR 40% and NNT 2.5. **Do not quote that NNT.** The control arm is **nine patients**, allocation was not randomized, and confounding by indication runs both directions — sicker patients get treated, and patients already improving do not. A confidence interval spanning 1.3 to 33.6 is the study telling you how little it knows. Hypothesis-generating, not an effect estimate. The negative studies are thought to reflect more severe disease and inclusion of steroid-unresponsive NSAID cases^([1,13](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

------------------------------------------------------------------------

## 6. The Non-Responder, and Where Rituximab Belongs

If the patient has not recovered 3–4 weeks after withdrawal plus steroids, work it in this order. PRACTICE-BASED

1.  **Question the diagnosis.** Consider alternative AKI etiologies, particularly if no biopsy was done. Biopsy now if feasible.
2.  **If biopsy-confirmed, read the chronicity.** This is the decision point.
3.  **If there is an active infiltrate** — extend the steroid course to a total of 8–12 weeks. Do not add a second agent yet.

The most commonly missed decision in AIN

**Severe chronic changes (heavy IFTA) with no acute inflammatory infiltrate: the patient will not improve. Taper and stop the glucocorticoids.** Adding immunosuppression here purchases infection risk, not GFR.

### 6.1 Mycophenolate EVIDENCE-BASED

**Dose: 1 g/day orally in divided doses, titrated to 2 g/day if tolerated.** The evidence is Preddie et al.^([7](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)) — **n=8**, treated 13–34 months. Those patients had **responded to steroids but could not tolerate withdrawal after six months**: steroid-*dependent*, not steroid-*resistant*. All were able to discontinue glucocorticoids; two failed to improve creatinine.

**The limitation that governs how far you can generalize: only two of the eight had drug-induced AIN.** Applying this series to classic drug AIN is a genuine extrapolation, not an established indication.

### 6.2 Rituximab — where it belongs and where it does not

Match the drug to the effector cell

**Not for ordinary drug-induced AIN** — that lesion is T-cell mediated, so B-cell depletion targets the wrong compartment, and the major drug-induced AIN reviews do not list it^([1,2,3](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

**Rational when the driver is antibody- or B-cell-mediated:** IgG4-related disease, where it has the strongest support^([28](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)); anti-TBM disease; and ABBA disease^([26](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

**Not standard for sarcoid**, where the pathway runs methotrexate, azathioprine, or MMF, then anti-TNF^([23](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

### 6.3 IgG4-related disease — the one randomized exception EVIDENCE-BASED

Most patients respond to glucocorticoids but **flare during or after taper**, so additional therapy is usually required. Rituximab's historical basis is an open-label, **single-arm** trial of 30 patients — no control group^([28](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)). That changed with **obexelimab**, a bifunctional anti-CD19/FcγRIIb antibody that inhibits rather than depletes B cells, reported in *NEJM* 2026^([30](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)): among 194 patients undergoing protocolized glucocorticoid withdrawal by week 8, disease flare over 52 weeks was **26.8% versus 54.6%** with placebo.

| Obexelimab, 52-week flare | Value               |
|---------------------------|---------------------|
| Control event rate        | 54.6%               |
| Treatment event rate      | 26.8%               |
| **RRR**                   | approximately 51%   |
| **ARR**                   | 27.8%               |
| **NNT**                   | **4** over 52 weeks |

Critical appraisal — obexelimab

Randomized, double-blind, placebo-controlled — a genuine methodological step up from the single-arm rituximab data. Two caveats to carry: the endpoint is **disease flare**, an intermediate outcome rather than organ survival or mortality; and the trial enrolled patients undergoing *protocolized steroid withdrawal*, which elevates the control-arm event rate and therefore inflates the absolute difference relative to ordinary practice.

------------------------------------------------------------------------

## 7. Supportive Care and the Prophylaxis Trap

PRACTICE-BASED PJP prophylaxis applies at prednisone 20 mg/day or above for four or more weeks, particularly alongside MMF.

Why TMP-SMX is the wrong default in this specific population

1.  **Sulfonamides are a classic AIN trigger.** If sulfa is anywhere on the suspect list, do not use it.
2.  **Trimethoprim inhibits tubular creatinine secretion**, raising creatinine 0.1–0.3 mg/dL with no change in true GFR — contaminating the exact measurement you are using to judge treatment response.

**Atovaquone 1500 mg daily avoids both.** Dapsone requires G6PD testing and is itself a DRESS trigger^([18](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)).

PRACTICE-BASED Before rituximab: HBsAg and anti-HBc (reactivation risk) and a baseline quantitative IgG. Also address bone protection for prolonged steroid courses, gastric protection *without a PPI* if the AIN was PPI-induced, and vaccination status before immunosuppression.

------------------------------------------------------------------------

## 8. Prognosis

PRACTICE-BASED Complete recovery in roughly 50–75% with prompt withdrawal; partial recovery 20–30%; progression to ESKD 5–10%, higher with delayed recognition.

EVIDENCE-BASED Predictors of poor recovery are consistent across series^([1,3,4](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources)):

1.  **Kidney failure lasting more than three weeks** before treatment
2.  **NSAID** as the causative agent
3.  **Interstitial granulomas, fibrosis, and tubular atrophy** on biopsy
4.  Mesalamine as the agent — frequently irreversible^([11,12](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html#verified-sources))

The one thing to take away

Time-to-withdrawal is the dominant modifiable variable. Steroids may accelerate recovery when started early; nothing rescues a kidney that has already fibrosed. When deciding whether to escalate immunosuppression, the biopsy chronicity — not the creatinine — casts the deciding vote.

------------------------------------------------------------------------

## Related Reading

- [AIN and GN Diagnostic Methodologies: From Clinical Suspicion to Kidney Biopsy](https://urinenephrology.org/mastery/aki-advanced/ain-gn-diagnostic-methodologies-review.html)
- [Drug-Induced AKI: Comprehensive Overview](https://urinenephrology.org/mastery/aki-advanced/drug-induced-aki-comprehensive-overview.html)
- [NSAID-Associated AKI](https://urinenephrology.org/mastery/aki-advanced/nsaid-aki.html)
- [AIN Lecture (PA-level)](https://urinenephrology.org/2025_UDPA_Lectures_Live/aki/interstitial-nephritis.html)
- [AIN Student Handout](https://urinenephrology.org/student-resources/aki/ain-student-handout.html)

### Sources

1.  **Moledina DG, Perazella MA.** Drug-induced acute interstitial nephritis. *Clin J Am Soc Nephrol.* 2017. [PMID: 28893923](https://pubmed.ncbi.nlm.nih.gov/28893923/)
2.  **Perazella MA, Markowitz GS.** Drug-induced acute interstitial nephritis. *Nat Rev Nephrol.* 2010. [PMID: 20517290](https://pubmed.ncbi.nlm.nih.gov/20517290/)
3.  **Praga M, González E.** Acute interstitial nephritis. *Kidney Int.* 2010. [PMID: 20336051](https://pubmed.ncbi.nlm.nih.gov/20336051/)
4.  **Muriithi AK, Leung N, Valeri AM, et al.** Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. *Am J Kidney Dis.* 2014;64(4):558-566. [PMID: 24927897](https://pubmed.ncbi.nlm.nih.gov/24927897/)
5.  **Muriithi AK, Nasr SH, Leung N.** Utility of urine eosinophils in the diagnosis of acute interstitial nephritis. *Clin J Am Soc Nephrol.* 2013;8(11):1857-1862. [PMID: 24052222](https://pubmed.ncbi.nlm.nih.gov/24052222/) *— verified full-text; source of the LR 0.97 / 1.01 figures.*
6.  **González E, Gutiérrez E, Galeano C, et al.** Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. *Kidney Int.* 2008;73(8):940-946. [PMID: 18185501](https://pubmed.ncbi.nlm.nih.gov/18185501/)
7.  **Preddie DC, Markowitz GS, Radhakrishnan J, et al.** Mycophenolate mofetil for the treatment of interstitial nephritis. *Clin J Am Soc Nephrol.* 2006;1(4):718-722. [PMID: 17699278](https://pubmed.ncbi.nlm.nih.gov/17699278/)
8.  **Fernández-Juárez G, Pérez JV, Caravaca-Fontán F, et al.** Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. *Clin J Am Soc Nephrol.* 2018;13(12):1851-1858. [PMID: 30397027](https://pubmed.ncbi.nlm.nih.gov/30397027/)
9.  **Moledina DG, Obeid W, Smith RN, et al.** Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. *J Clin Invest.* 2023. [PMID: 37395276](https://pubmed.ncbi.nlm.nih.gov/37395276/)
10. **Lazarus B, Chen Y, Wilson FP, et al.** Proton pump inhibitor use and the risk of chronic kidney disease. *JAMA Intern Med.* 2016;176(2):238-246. [PMID: 26752337](https://pubmed.ncbi.nlm.nih.gov/26752337/)
11. **Moss JG, et al.** 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. *Eur J Med Res.* 2022. [PMID: 35488310](https://pubmed.ncbi.nlm.nih.gov/35488310/)
12. **Adiga A, Nugent K.** The association of mesalamine with kidney disease. *Adv Chronic Kidney Dis.* 2020. [PMID: 32147005](https://pubmed.ncbi.nlm.nih.gov/32147005/)
13. **Klomjit N, Manohar S.** Acute kidney injury associated with non-steroidal anti-inflammatory drugs. *Eur J Intern Med.* 2022. [PMID: 35534373](https://pubmed.ncbi.nlm.nih.gov/35534373/)
14. **Cortazar FB, Kibbelaar ZA, Glezerman IG, et al.** Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. *J Am Soc Nephrol.* 2020;31(2):435-446. [PMID: 31896554](https://pubmed.ncbi.nlm.nih.gov/31896554/)
15. **Cortazar FB, Marrone KA, Troxell ML, et al.** Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. *Kidney Int.* 2016;90(3):638-647. [PMID: 27282937](https://pubmed.ncbi.nlm.nih.gov/27282937/)
16. **Barbir EB, et al.** Immune checkpoint inhibitor-associated nephritis — treatment standard. *Nephrol Dial Transplant.* 2024. [PMID: 39138117](https://pubmed.ncbi.nlm.nih.gov/39138117/)
17. **Ng CY, Yeh YT, Wang CW, et al.** Impact of the HLA-B\*58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. *J Invest Dermatol.* 2016;136(7):1373-1381. [PMID: 26996548](https://pubmed.ncbi.nlm.nih.gov/26996548/)
18. **Kardaun SH, Sekula P, Valeyrie-Allanore L, et al.** Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. *Br J Dermatol.* 2013;169(5):1071-1080. [PMID: 23855313](https://pubmed.ncbi.nlm.nih.gov/23855313/)
19. **De Vriese AS, Robbrecht DL, Vanholder RC, et al.** Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. *Am J Kidney Dis.* 1998;31(1):108-115. [PMID: 9428460](https://pubmed.ncbi.nlm.nih.gov/9428460/)
20. **Joss N, Morris S, Young B, Geddes C.** Granulomatous interstitial nephritis. *Clin J Am Soc Nephrol.* 2007;2(2):222-230. [PMID: 17699417](https://pubmed.ncbi.nlm.nih.gov/17699417/)
21. **Luciano RL, Perazella MA.** Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment. *Drug Saf.* 2015;38(1):55-64. [PMID: 25446374](https://pubmed.ncbi.nlm.nih.gov/25446374/)
22. **Kotton CN, Kamar N, Wojciechowski D, et al.** The second international consensus guidelines on the management of BK polyomavirus in kidney transplantation. *Transplantation.* 2024. [PMID: 38605438](https://pubmed.ncbi.nlm.nih.gov/38605438/)
23. **Calatroni M, Moroni G, Conte E, et al.** Renal sarcoidosis. *J Nephrol.* 2023. [PMID: 35761015](https://pubmed.ncbi.nlm.nih.gov/35761015/)
24. **Chatterjee R, et al.** Renal involvement in Sjögren's syndrome: predictors and impact on patient outcomes. *Rheumatol Int.* 2023. [PMID: 36650312](https://pubmed.ncbi.nlm.nih.gov/36650312/)
25. **Amaro D, Carreño E, Steeples LR, et al.** Tubulointerstitial nephritis and uveitis (TINU) syndrome: a review. *Br J Ophthalmol.* 2020;104(6):742-747. [PMID: 31719109](https://pubmed.ncbi.nlm.nih.gov/31719109/)
26. **Dvanajscak Z, Cossey LN, Larsen CP, et al.** Anti-brush border antibody disease (anti-LRP2 nephropathy) associated with lupus nephritis. *Kidney Int Rep.* 2020. [PMID: 32954086](https://pubmed.ncbi.nlm.nih.gov/32954086/)
27. **Sahutoglu T, et al.** Update on acute tubulointerstitial nephritis: clinical features, immunologic insights, and diagnostic and treatment approaches. *Kidney Int Rep.* 2025. [PMID: 40630288](https://pubmed.ncbi.nlm.nih.gov/40630288/)
28. **Carruthers MN, Topazian MD, Khosroshahi A, et al.** Rituximab for IgG4-related disease: a prospective, open-label trial. *Ann Rheum Dis.* 2015;74(6):1171-1177. [PMID: 25667206](https://pubmed.ncbi.nlm.nih.gov/25667206/)
29. **Isnard P, Rabant M, Labaye J, et al.** Karyomegalic interstitial nephritis: a case report and review of the literature. *Medicine (Baltimore).* 2016;95(11):e3181. [PMID: 27196444](https://pubmed.ncbi.nlm.nih.gov/27196444/)
30. **Della-Torre E, et al.** Obexelimab for the treatment of IgG4-related disease. *N Engl J Med.* 2026. [PMID: 42233621](https://pubmed.ncbi.nlm.nih.gov/42233621/)
31. **Sadarangani S, et al.** Diagnosing acute tubulointerstitial nephritis: novel biomarkers address an important clinical challenge. *Curr Opin Nephrol Hypertens.* 2026. [PMID: 41460039](https://pubmed.ncbi.nlm.nih.gov/41460039/)

------------------------------------------------------------------------

*Last updated: 2026-07-30* *For questions or updates, contact: [send a comment or correction to the author](https://urinenephrology.org/author-feedback.html?page=%2Fmastery%2Faki-advanced%2Facute-interstitial-nephritis-comprehensive.html&title=Acute+Interstitial+Nephritis%3A+Complete+Etiology+and+Etiology-Directed+Treatment+%E2%80%94+Medical+Education+Handout)*


---

[Website version](https://urinenephrology.org/mastery/aki-advanced/acute-interstitial-nephritis-comprehensive.html) · Markdown synchronized October 3, 2026.